Inactive therapy replicating active therapy.
1No apparent decrease in IgG-CIC or IgA-CIC was observed with placebo treatment.
2Results: No significant changes occurred in any parameters after placebo treatment.
3Differences in outcome prediction between diuretic, β-blocker and placebo treatment arms were investigated.
4Levetiracetam therapy decreased significantly the frequency of seizures compared with the placebo treatment.
5Results: After placebo treatment, the response to methacholine was similar at each time point.
6The mild effect of the placebo treatment is explained by the treatment procedure itself.
7Interpretation: Chlorhexidine skin treatment produced more extended skin cleansing effects than the placebo treatment.
8The placebo efficacy of romazarit treatment was similar to that associated with placebo treatment.
9The outcome of placebo treatment was poor in most studies.
10The safety profile during treatment was similar to that observed in patients receiving placebo treatment.
11Results: Eighteen patients received mepolizumab and 22 placebo treatment.
12Insulin sensitivity was assessed by the minimal model after 10 weeks of doxazosin or placebo treatment.
13No adverse events occurred during placebo treatment.
14Six control animals received placebo treatment.
15Evaluation of the 7-year outcomes of the RITUX-ERAH study patients according to the rituximab or placebo treatment received.
16Methods: Subjects were randomized to receive CXL as in the standard protocol for treating keratoconus or a placebo treatment.